MedTrace Logo

Impact of HPV Vaccination on HPV Infection and Cervical Related Disease Burden in Real-World Settings (HPV-RWS)

NCT05341284 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-08-14

No results posted yet for this study

Summary

Take AS04 adjuvanted HPV16/18 vaccine as an example to evaluate the impact of HPV vaccination on HPV infection and related disease burden in the real world based on prospective cohort and Yinzhou Regional Health Information Platform (YRHIP), in order to bridge the gap in relevant evidence in China.

Conditions

Interventions

OTHER

Questionnaire Survey and Cervical Cancer Screening

A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36. For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36.

Sponsors & Collaborators

  • Center for Disease Control and Prevention of Yinzhou District, Ningbo City, China

    collaborator UNKNOWN

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Eligibility

Min Age
9 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2022-08-01
Completion
2022-08-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05341284 on ClinicalTrials.gov